Biota inks Sankyo deal

By Jeremy Torr
Tuesday, 27 May, 2003

Biota has signed a letter of intent with Japanese pharma Sankyo to collaborate on the development of small molecule long-acting neuraminidase inhibitor (LANI) drugs.

Under the proposed collaboration, Biota and Sankyo will pool their LANI pipelines, cross-license patents, and share in licensing and royalty revenues.

"This is an important strategic alliance for Biota. The agreement effectively accelerates our Flunet program and gives us a major boost in the partnering process. It also gives us a potential new source of revenues, bridging our marketed products and our discovery stage programs," commented Biota CEO Peter Molloy.

Molloy described the agreement as "an attractive licensing package", and noted that it covered a strong patent element along with several compounds. Under the proposed agreement, the companies will jointly manage the partnering process, with the intention that all further clinical development work would be funded by licensing partners seeking to market the drugs.

Sankyo has developed its own long-acting neuraminidase inhibitor (LANI) which is already in Phase I human clinical trials in Europe. Biota's Flunet compound is at pre-clinical stage, with the first output from the combined research likely to enter Phase II trials in 2004.

Related News

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...

Towards safer epilepsy treatment for pregnant women

New research conducted in organoids is expected to provide pregnant women with epilepsy safer...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd